Leap Therapeutics Completes $58.88 Million Cash Private Placement Led by Winklevoss Capital
biotechnology company Leap Therapeutics (NASDAQ stock code: LPTX) announced today that it has completed the previously announced private placement led by Winklevoss Capital, raising $58,888,888 in cash to launch its digital asset financial strategy. Winklevoss Capital will provide funding and strategic support to help Leap build and execute its digital asset financial strategy. Under the lead investor agreement, the Leap board of directors will increase to 12 members, Winklevoss Capital will have the right to nominate two individuals to the Leap board of directors, one of whom will also serve as chairman of the board. Morgan, Lewis & Bockius LLP serves as Leap's legal counsel, and Cooley LLP serves as Winklevoss Capital's legal counsel.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP RealFi Launch Shows Potential to Replace Swift Payments
Quick Take Summary is AI generated, newsroom reviewed. XRP is under review to potentially replace the U.S. Swift system. RealFi’s Real Token may unlock $650 trillion in global liquidity on the XRP Ledger. XRP could see price surges if adoption expands. Investors should monitor market activity and prepare for volatility.References XRP IS UNDER REVIEW TO REPLACE THE U.S. SWIFT SYSTEM — UNLOCKING A $1.5 QUADRILLION MARKET!
Bitwise Bear Market Outlook Improves as XRP ETF Nears Launch
Solana price forms death cross as SOL ETF inflows near $400m

Trump Crypto Statement Signals America’s Vision in Digital Assets
